Get Schooled In Anaphylaxis™, Mylan Specialty
A contest to help raise awareness about anaphylaxis sponsored by Mylan Specialty. The below is a press release. [Disclosure: I have a relationship with Mylan Specialty]:
“Modern Family” Star Julie Bowen Joins Mylan Specialty L.P. to Launch Health Awareness Initiative to Address Growing Rate of Life-Threatening Allergic Reactions
Get Schooled In Anaphylaxis™ Campaign Kicks Off with College Scholarship Challenge
Basking Ridge, NJ, September 26, 2012 – Emmy-award winning actress Julie Bowen, known for her comedic role in “Modern Family,” is for the first time publicly sharing her family’s experience with life-threatening allergies to help drive a national conversation on this serious health issue. Bowen is partnering with Mylan Specialty L.P. to launch Get Schooled in Anaphylaxis™, a multi-faceted public health initiative that aims to increase awareness of and preparedness for life-threatening allergic reactions (anaphylaxis). To view the multimedia content, please click: http://www.multivu.com/players/English/57462-get-schooled-in-anaphylaxis/
The campaign’s first priority will be to focus on educating the school community. To get the school community involved, Bowen is calling on students nationwide to join the Get Schooled in Anaphylaxis Challenge™. Students in grades 1-12 are encouraged to visit www.Anaphylaxis101.com and submit an essay describing an idea to help their school become more aware of and better prepared to support students who may be at risk for life-threatening allergic reactions. Fifteen students from across the country will be selected by a judging panel to win a $2,000 college scholarship.
Get Schooled In Anaphylaxis Challenge™ Entry Information
The Get Schooled in Anaphylaxis Challenge™ encourages school-aged children in grades 1-12 to write a brief essay and submit up to two visual images. Submissions should explain an idea to:
· Improve awareness of life-threatening allergies in schools;
· Help students who may be at risk for life-threatening allergic reactions feel more accepted in their school; or
· Provide a unique solution to a challenge faced by students who may be at risk for anaphylaxis.
Each entry will be evaluated by a judging panel including family caregivers, doctors, school nurses, advocacy groups and others in the allergy community. Winners will be selected based on creativity and originality of the idea, the clarity of the proposed solution and the potential for implementation of the idea.
Essays can be submitted from September 26, 2012 to November 9, 2012.
For more information visit www.Anaphylaxis101.com.
Get Schooled in Anaphylaxis™
The Get Schooled in Anaphylaxis™ initiative offers practical information to educate the school community to help those at risk for life-threatening allergic reactions avoid their triggers, recognize anaphylaxis signs and symptoms and understand how to quickly get appropriate treatment and immediate medical care when anaphylaxis occurs. Visit www.Anaphylaxis101.com to explore how anaphylaxis can affect the entire school community and learn more about life-threatening allergic reactions. You can also download practical tools, learn more about Julie Bowen’s family story and watch a PSA featuring the actress, and sign up to receive news about campaign activities and events.
More About Anaphylaxis
Anaphylaxis is a life-threatening allergic reaction that can occur when the body is exposed to an allergen. Symptoms may include trouble breathing, chest pain, skin hives or redness of the skin, tightness in the throat, swelling of the lips and/or tongue, nausea, dizziness, a decrease in blood pressure, and/or fainting. Anaphylaxis symptoms may progress rapidly and become life-threatening, requiring prompt recognition and treatment initiation. While avoidance of allergic triggers is the critical first step in managing life-threatening allergies, allergens are not always obvious, and accidental exposure may still happen. Food allergy guidelines developed by National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), recommend epinephrine as the only first-line treatment for anaphylaxis management and that it be available at all times to those at risk for anaphylaxis. If experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Delays in instituting therapy with epinephrine are associated with risks of death and morbidity.
About Mylan Specialty
Mylan Specialty, a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.mylanspecialty.com.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide seven billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what’s right, not what’s easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don’t take our word for it. See for yourself. See inside. Mylan.com.
Get Schooled in Anaphylaxis™ and Get Schooled in Anaphylaxis Challenge™ are sponsored by and trademarks of Mylan Specialty L.P. © 2012. All rights reserved. MYS12-8001